Sildenafil Tablet
Product Images NDC 63629-5029

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Sildenafil (NDC 63629-5029). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Lbl636295029

Label for Sildenafil Citrate 20 mg Tablet by Bryant Ranch Prepack, comparing to Revatio 20 mg Tablet by Amneal Pharmaceuticals Pvt Ltd. The label includes storage instructions at room temperature 20°-25°C (68°-77°F), a warning to keep drugs out of reach of children, and states RX only. The tablet is described as white, round.*

FDA Label Image

Sildenafil Tablets 20mg 1

A Kaplan-Meier curve graph showing estimated cumulative mortality rate (%) over time in years for three dosing groups: High Dose, Medium Dose, and Low Dose. The chart includes stepwise lines representing mortality progression and a table indicating the number at risk at each time point for each group.*

FDA Label Image

Sildenafil Tablets 20mg 2

Chemical structure of Sildenafil, the active ingredient in the medication Sildenafil 20 mg oral tablets by Bryant Ranch Prepack. The diagram shows the molecular layout and bonding of the compound's atoms as commonly depicted in chemical notation.*

FDA Label Image

Sildenafil Tablets 20mg 3

A forest plot chart showing fold change with 90% confidence intervals for area under the curve (AUC) and maximum concentration (Cmax) of Sildenafil when co-administered with various interacting drugs. The chart includes drugs like Atorvastatin, Azithromycin, Bosentan, Cimetidine, Erythromycin, Maalox, Oral Contraceptives, Ritonavir, and Saquinavir, with recommendations on dose adjustments for each interaction.*

FDA Label Image

Sildenafil Tablets 20mg 4

A forest plot showing fold change and 90% confidence intervals (CI) for various interacting drugs with Sildenafil, comparing pharmacokinetic parameters like AUC, Cmax, INR, and bleeding time. It includes recommendations for dose adjustment, mostly indicating no dose adjustment except for ritonavir where coadministration is not recommended. The x-axis represents change relative to the interacting drug alone, centered at 1.*

FDA Label Image

Sildenafil Tablets 20mg 5

A line chart comparing changes from baseline over 4, 6, and 12 weeks for four groups: Sildenafil 40mg TID, Sildenafil 20mg TID, Sildenafil 60mg TID, and placebo. The vertical axis represents change from baseline in meters with error bars indicating variability around the mean values.*

FDA Label Image

Sildenafil Tablets 20mg 6

A forest plot chart showing placebo-corrected changes in 6-minute walk distance (meters) for Sildenafil 20 mg taken three times daily (TID) across different subgroups. The subgroups include baseline walk distance, etiology of pulmonary arterial hypertension (PAH), functional capacity class, gender, age, mean pulmonary arterial pressure (PAP), and pulmonary vascular resistance index (PVRI). The plot displays point estimates and confidence intervals for each category and subgroup.*

FDA Label Image

Sildenafil Tablets 20mg 7

A line graph showing the percentage of subjects without a clinically worsening event over time (days from randomization) comparing Sildenafil and placebo. The y-axis indicates the percentage without worsening, ranging from 0 to 100%, and the x-axis shows days from 0 to 112. Sildenafil is represented by a dashed line, and placebo by a solid line, with Sildenafil maintaining higher percentages of subjects without clinical worsening throughout the period.*

FDA Label Image

Sildenafil Tablets 20mg 8

A line graph depicting mean change from baseline (in meters) over weeks 4, 8, and 12 for Sildenafil tablets at 1 mg TID, 5 mg TID, and 20 mg TID dosages. The graph shows standard error bars for each treatment group at each visit up to week 12.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.